NeuExo Therapeutics is a biotechnology company focused on developing exosome-based therapeutics for neurodegenerative diseases, with a primary focus on Parkinson's disease. The company leverages natural extracellular vesicle (exosome) delivery systems to transport therapeutic cargo—including microRNAs, proteins, and small molecules—across the blood-brain barrier to target neurons affected by neurodegeneration.
Company Information
...
Overview
Mermaid diagram (expand to render)
NeuExo Therapeutics is a biotechnology company focused on developing exosome-based therapeutics for neurodegenerative diseases, with a primary focus on Parkinson's disease. The company leverages natural extracellular vesicle (exosome) delivery systems to transport therapeutic cargo—including microRNAs, proteins, and small molecules—across the blood-brain barrier to target neurons affected by neurodegeneration.
Company Information
| Attribute | Details | |-----------|---------| | Headquarters | Cambridge, Massachusetts, USA | | Founded | 2021 | | Focus | Exosome-based therapeutics for neurodegenerative disease | | Lead Indication | Parkinson's disease | | Website | https://www.neuexotherapeutics.com |
Technology Platform
Exosome Engineering Platform
NeuExo has developed a proprietary platform for engineering therapeutic exosomes:
Cargo Loading: Proprietary methods for loading exosomes with therapeutic molecules
Targeting: Surface modification of exosomes for neuron-specific targeting
Manufacturing: Scalable production of clinical-grade exosomes
Quality Control: Standardized protocols for batch-to-batch consistency
Exosome Advantages
Exosomes offer several advantages for CNS drug delivery:
Blood-brain barrier penetration: Natural ability to cross the BBB
Low immunogenicity: Reduced immune response compared to viral vectors
Cellular targeting: Can be engineered to target specific neural cell types
Cargo versatility: Can deliver proteins, RNAs, small molecules, and nucleotides
Repeat dosing: Feasible due to favorable safety profile
Pipeline Programs
Lead Program: miR-124 Delivery for PD
NeuExo's lead program uses exosome-mediated delivery of miR-124 for Parkinson's disease:
Mechanism: miR-124 is the most abundant miRNA in the brain and plays critical roles in neuronal survival. In PD, miR-124 expression is significantly reduced in dopaminergic neurons.
Therapeutic rationale: Restoring miR-124 levels can promote neuronal survival, enhance autophagy and lysosomal function, and reduce neuroinflammation.
Delivery: Exosomes provide natural delivery across the BBB to target neurons in the substantia nigra and striatum
Stage: Preclinical development
Supporting Science
The therapeutic approach is supported by peer-reviewed research:
Exosome-mediated delivery of miR-124 has demonstrated neuroprotection in PD models[@mirna124exosome2021]
miR-124 targets multiple pathways relevant to PD pathogenesis including UBE2A, BAX, and SCARB2[@mirna124pd2023]
Exosome biology provides natural mechanisms for CNS delivery[@exosomebbb2023]